GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aldeyra Therapeutics Inc (NAS:ALDX) » Definitions » Cyclically Adjusted FCF per Share

Aldeyra Therapeutics (Aldeyra Therapeutics) Cyclically Adjusted FCF per Share : $-1.35 (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Aldeyra Therapeutics Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Aldeyra Therapeutics's adjusted free cash flow per share for the three months ended in Mar. 2024 was $-0.168. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-1.35 for the trailing ten years ended in Mar. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2024-05-28), Aldeyra Therapeutics's current stock price is $3.79. Aldeyra Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was $-1.35. Aldeyra Therapeutics's Cyclically Adjusted Price-to-FCF of today is .


Aldeyra Therapeutics Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Aldeyra Therapeutics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aldeyra Therapeutics Cyclically Adjusted FCF per Share Chart

Aldeyra Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - -1.57 -1.34

Aldeyra Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.49 -1.40 -1.36 -1.34 -1.35

Competitive Comparison of Aldeyra Therapeutics's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, Aldeyra Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aldeyra Therapeutics's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aldeyra Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Aldeyra Therapeutics's Cyclically Adjusted Price-to-FCF falls into.



Aldeyra Therapeutics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Aldeyra Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.168/131.7762*131.7762
=-0.168

Current CPI (Mar. 2024) = 131.7762.

Aldeyra Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -0.237 100.560 -0.311
201409 -0.218 100.428 -0.286
201412 -0.288 99.070 -0.383
201503 -0.277 99.621 -0.366
201506 -0.194 100.684 -0.254
201509 -0.300 100.392 -0.394
201512 -0.309 99.792 -0.408
201603 -0.462 100.470 -0.606
201606 -0.307 101.688 -0.398
201609 -0.281 101.861 -0.364
201612 -0.311 101.863 -0.402
201703 -0.304 102.862 -0.389
201706 -0.351 103.349 -0.448
201709 -0.302 104.136 -0.382
201712 -0.262 104.011 -0.332
201803 -0.418 105.290 -0.523
201806 -0.319 106.317 -0.395
201809 -0.369 106.507 -0.457
201812 -0.304 105.998 -0.378
201903 -0.467 107.251 -0.574
201906 -0.475 108.070 -0.579
201909 -0.307 108.329 -0.373
201912 -0.406 108.420 -0.493
202003 -0.526 108.902 -0.636
202006 -0.252 108.767 -0.305
202009 -0.165 109.815 -0.198
202012 -0.215 109.897 -0.258
202103 -0.295 111.754 -0.348
202106 -0.167 114.631 -0.192
202109 -0.145 115.734 -0.165
202112 -0.199 117.630 -0.223
202203 -0.221 121.301 -0.240
202206 -0.342 125.017 -0.360
202209 -0.215 125.227 -0.226
202212 -0.192 125.222 -0.202
202303 -0.161 127.348 -0.167
202306 -0.227 128.729 -0.232
202309 -0.136 129.860 -0.138
202312 0.008 129.419 0.008
202403 -0.168 131.776 -0.168

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Aldeyra Therapeutics  (NAS:ALDX) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Aldeyra Therapeutics Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Aldeyra Therapeutics's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Aldeyra Therapeutics (Aldeyra Therapeutics) Business Description

Industry
Traded in Other Exchanges
Address
131 Hartwell Avenue, Suite 320, Lexington, MA, USA, 02421
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer.
Executives
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Todd C Brady director, officer: President and CEO C/O EVOKE PHARMA, INC., 505 LOMAS SANTA FE DRIVE, SOLANA BEACH CA 92075
Martin Joseph Joyce director 1050 HINGHAM STREET, ROCKLAND MA 02370
Bruce Greenberg officer: See Remarks C/O ALDEYRA THERAPEUTICS, INC., 131 HARTWELL AVENUE, SUITE 320, LEXINGTON MA 02421
Stephen Machatha officer: Chief Development Officer 131 HARTWELL AVENUE, SUITE 320, LEXINGTON MA 02421
Joseph Edelman 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Richard Douglas director ONE KENDALL SQUARE, CAMBRIDGE MA 02139
Nancy Miller-rich director C/O INTERCEPT PHARMACEUTICALS, INC., 10 HUDSON YARDS, 37TH FL, NEW YORK NY 10001
Ben Bronstein director 15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803
David J Clark officer: Chief Medical Officer 131 HARTWELL AVE, LEXINGTON MA 02421
David Mcmullin officer: SVP Corp. Dev. & Strategy C/O ALDEYRA THERAPEUTICS, INC., 131 HARTWELL AVENUE, SUITE 320, LEXINGTON MA 02421
Joshua Reed officer: Chief Financial Officer C/O ALDEYRA THERAPEUTICS, INC., 131 HARTWELL AVENUE, SUITE 320, LEXINGTON MA 02421
Jesse I Treu director, 10 percent owner
Stephen J Tulipano officer: Chief Financial Officer C/O JAVELIN PHARMACEUTICALS, INC., 125 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140

Aldeyra Therapeutics (Aldeyra Therapeutics) Headlines

From GuruFocus